Available Until 12/31/2022

Managed Care Perspectives for the Rapidly Evolving Oncology Landscape

Course Description:

Innovation in oncology is occurring at a swift pace, with ever-expanding options and promise of improved outcomes. Many oncolytic agents recently approved by the Food and Drug Administration or pending approval in coming months are considered to be breakthrough therapies, offer extended indications, or are formulations changing the place of care. Managing the increasing number of high-cost agents, determining value and outcomes, and minimizing toxicities pose challenges when developing utilization policies for these valuable advances in treatment. 

During this session, faculty will highlight recently approved oncology indications or novel mechanisms of action, discuss the place in therapy for these newly approved agents, and focus on managed care considerations related to payment models, access to care, and oncology care pathways. This session will also explore emerging therapies in the oncology pipeline. 

Learning Objectives 

At the completion of this activity, participants should be able to: 

  • Identify recently approved high impact oncology agents with novel indications for use or targeted mechanisms of action.  
  • Discuss the potential place in therapy of oncology agents likely to be approved in the next six months. 
  • Review the financial and operational impact of newly approved therapies on patients, care providers, and health plans 
  • Distinguish formulary considerations for newly approved and emerging oncology treatments

Target Audience 

This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings. 


Timothy Mok, PharmD, BCPS, BCOP

Hematology Oncology Pharmacy Research Analyst  

Kaiser Permanente 

Livermore, California 

Philip Schwieterman, PharmD, MHA 


University of Kentucky Healthcare 

Lexington, Kentucky 


Jonny Clark, PharmD 


Blue Fin Group

Saint Petersburg, Florida 


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN:0233-0000-22-022-H01-P   • Activity Type: Knowledge-Based
Contact Hours: 1
Release Date: May 11, 2022 •  Expiration Date: December 31, 2023
Activity Fee: Free for Members and $50 for Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at eLearning Days 2022. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-22-025-H01-P 1 Contact Hour May 10, 2022 - December 31, 2023